A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

(2022) Xinyi Li et al.   Molecular Cancer

Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP

(2021) Mengzhu Zheng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis

(2020) Mengzhu Zheng et al.   PHARMACOLOGICAL RESEARCH

MiR-885-5p Negatively Regulates Warburg Effect by Silencing Hexokinase 2 in Liver Cancer

(2019) Fei Xu et al.   Molecular Therapy-Nucleic Acids

Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin

(2018) Dannielle DeWaal et al.   Nature Communications

VDAC1 as Pharmacological Target in Cancer and Neurodegeneration: Focus on Its Role in Apoptosis

(2018) Andrea Magrì et al.   Frontiers in Chemistry

MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53

(2018) John Hines et al.   CANCER RESEARCH

Unlocking the potential of HK2 in cancer metabolism and therapeutics

(2018) Sara N. Garcia et al.   CURRENT MEDICINAL CHEMISTRY

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

(2018) Yangbing Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2

(2017) Wei Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

(2017) Ian Churcher   JOURNAL OF MEDICINAL CHEMISTRY

The Emerging Hallmarks of Cancer Metabolism

(2016) Natalya N. Pavlova et al.   Cell Metabolism

Induced protein degradation: an emerging drug discovery paradigm

(2016) Ashton C. Lai et al.   NATURE REVIEWS DRUG DISCOVERY

Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of Cancer

(2013) Krushna C. Patra et al.   CANCER CELL

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

(2013) Gregg L. Semenza   JOURNAL OF CLINICAL INVESTIGATION

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL